Camber unveils generic Valcyte
PISCATAWAY, N.J. – Camber Pharmaceuticals announced the addition of valganciclovir for oral solution to its current portfolio. Valganciclovir for oral solution is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients: • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients
